🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Thanks for the shoutout. Couldn’t have done it without Pavlos Msaouel and many others.

Here’s our latest review on advances in targeted therapy for prostate cancer led by Kabir Grewal, MD shorturl.at/D1Isp We discuss tx targeting DDR, novel AR-directed tx, and innovations to target cell surface proteins

🎯 DART trial: SBRT vs SBRT + 6mo Darolutamide for oligorecurrent #prostatecancer. QoL results at #ESTRO25 ✅ Grade 3 events are low in both arms ✅ QoL remains stable after SBRT ❌ Gynecomastia biggest issue with darolutamide

Fascinating study showing no benefit with neoadj, concurrent, and adjuvant durva with sbrt for oligomet CRPC from Supiot Stéphane. Wonder if IO timing with RT affects outcomes. Credit to Neil Desai for being at #estro2025.

Can liquid biopsy guide treatment in oligorecurrent #Pca? In #RADIOSA we explored if a mutational signature in cfDNA predicts outcomes: - HR mutations (BRCA1/2, ATM, TP53, etc.) = ↓PFS - 19 mo vs 35 mo without HRM Liquid biopsy may help identify pts needing > intense treatment

Nivolumab concurrent and adjuvant with TMT may improve bladder PFS and OS in MIBC receiving bladder preservation protocol. Small randomized phase II trial presented at #ESTRO25 Waiting for GETUG BLADDER SPARING with atezo and larger phase III trials. Paul Sargos

Practical Considerations for the Treatment of Primary Renal Cell Carcinoma With SABR - ScienceDirect ⁦Shankar Siva⁩ ⁦James Yu⁩ ⁦Chad Tang, MD⁩ ⁦ sciencedirect.com/science/articl…

Stefano Arcangeli Neil Desai Thanks for listening to talk - few highlight slides here. Credit goes to great collaborators across trial group @ UMichigan, UPenn, Cleveland Clinic, U Colorado, Stony Brook, UCSF and UTSW

Appreciate everyone tuning into this wonderful multidisciplinary discussion on localized kidney cancer led by Joel Stern and JNFoundation.

Re-irradiation is common but challenging in lung cancer. ARS just published: American Radium Society™ Appropriate Use Criteria Systematic Review and Guidelines on Reirradiation for Non-small Cell Lung Cancer Executive Summary. My personalized Share Link: authors.elsevier.com/c/1l3k51Hx52Ni…

Hypofractionated, Dose-Escalated Radiation ☢️ Versus Conventionally Fractionated Radiation for Localized Prostate Cancer ascopubs.org/doi/abs/10.120… The MD Anderson phase III randomized trial compared conventional (CIMRT) versus dose-escalated, hypofractionated (HIMRT)

💥📣Read our Editorial! SBRT a rising ally in RCC care! Following the systematic review by Nora Sundahl Shankar Siva Chad Tang, MD sciencedirect.com/science/articl…

Had a wonderful time at #BMUC25 in Belgium. Appreciate the generous invitation from Piet Ost and the chance to talk about oligometastatic GU cancers. Amazing time exploring Belgium, especially during Brussels pride. Special thanks to Luc Van Ruysevelt and e-hims for organizing.

Happily surprised in MD Anderson Cancer Center clinic today! Thanks to my wonderful staff. Philippine food as per clinic tradition.

Congrats to the MD Anderson Cancer Center radiation oncology class of 2025. Honored to get the James Cox mentoring award. Thanks Alexander Sherry and Aaron Seo for being amazing mentees.

Great crew! Love it when they hang out with us for their week in rad onc.

💥We're thrilled to partner with ASTRO for a special joint session on radiotherapeutic innovations in #kidneycancer! Register for #ASTRO25 (early rate ends today) in September and join us for an exciting panel and discussion! 👉astro.org/meetings-and-e…

1/5 #RenalMedullaryCarcinoma (RMC) is a lethal #KidneyCancer in young people with #SickleCellTrait (SCT). Our new prospective study Urologic Oncology asks: does VIGOROUS exercise raise risk? 👉pubmed.ncbi.nlm.nih.gov/40617795/ #MsaouelLab

Essentials for hurricane season in Texas H-E-B. Water and Brisket.

Yup what a ride. Still got a some more to go. Appreciate our study team, our awesome med oncs who support the trial Pavlos Msaouel Andy Hahn Omar Alhalabi, MD (many more not on X), and of course our patients.